HIV Infections Clinical Trial
To detect by Doppler echocardiography the incidence of cardiac abnormalities in HIV-positive patients in a prospective, longitudinal study.
BACKGROUND:
Cardiovascular abnormalities have been reported in Acquired Immunodeficiency Syndrome (AIDS)
clinically, echocardiographically and at autopsy. Pericardial effusion, cardiac tamponade,
echocardiographic abnormalities and clinical cardiomyopathy with right and left-sided
congestive heart failure have all been reported as isolated case reports or in small
retrospective series of patients with AIDS who had echocardiograms. The frequency with which
abnormalities specifically related to AIDS were found in consecutively studied patients was
not known in 1988 when the study began.
The etiology of these abnormalities was also unclear. Since HIV infection resulted in
profound suppression of T-cell macrophage-mediated immunity in AIDS and since there were
significant abnormalities in B-cell lymphocyte function resulting in abnormalities of
humoral immunity, there were frequently life threatening superinfections by bacterial,
fungal, parasitic, and viral organisms. Some of these, such as herpes simplex,
cytomegalovirus, cryptococcosis, toxoplasmosis and histoplasmosis, were known to cause
pericarditis and myocarditis in the absence of AIDS so the presence of definite myocardial
disease in AIDS did not prove that the disease was due to the HIV organism.
Using echocardiography to study cardiac structure and function in a small series of patients
with AIDS, abnormalities have been identified in from 25 to 75 percent of patients. All of
these studies were retrospective; none was prospective with controls. Furthermore, all types
of echocardiographic abnormalities have been described including the presence of pericardial
fluid, mitral valve prolapse, chamber size abnormalities, and wall motion abnormalities.
Although these abnormalities could have been due to infection with the HIV organism there
were many other possible reasons for the echocardiographic abnormalities. Among AIDS
patients there was a high incidence of intravenous drug and alcohol abuse, patients in whom
cardiac abnormalities were common.
Since there were no echocardiographic studies comparing HIV antibody- positive groups of
patients to appropriate controls, it was not known whether the high reported incidence of
echocardiographic abnormalities was related specifically to the HIV infection, to
superinfection with other organisms, or was related to factors other than AIDS.
This project was part of an Institute-initiated study on AIDS-Associated Heart Disease in
Adults. In September 1987 the concept was approved by the National Heart, Lung, and Blood
Advisory Council and a Request for Applications was released. Awards were made in July 1988.
DESIGN NARRATIVE:
Patients were recruited from the in-patient out-patient clinics and wards of the San
Francisco General Hospital and the Moffitt-Long Hospitals. A medical history was obtained
and a physical examination conducted which included an electrocardiogram, chest x-rays and
Doppler echocardiogram. All studies were repeated every four months for four years in
HIV-positive groups. If clinical evidence of cardiac disease appeared, all studies including
chest x-ray were repeated at that time. If there was normal systolic function in patients
with definite left ventricular failure, a radionuclide angiogram was obtained to further
evaluate left ventricular diastolic function.
The study completion date listed in this record was obtained from the "End Date" entered in
the Protocol Registration and Results System (PRS) record.
;
N/A
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |